Breast Surgery Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK.
Department of Surgery, Uppsala University Hospital - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Ann Surg Oncol. 2022 Oct;29(10):6440-6453. doi: 10.1245/s10434-022-12197-6. Epub 2022 Jul 18.
The standard surgical management of ipsilateral breast cancer recurrence (IBCR) in patients previously treated with breast-conserving surgery (BCS) and radiotherapy (RT) is mastectomy. Recent international guidelines provide conflicting recommendations. The aim of this study was to perform a systematic literature review and meta-analysis of the oncological outcomes in patients with IBCR treated with repeat BCS (rBCS).
The MEDLINE and EMBASE databases were searched for relevant English-language publications, with no date restrictions. All relevant studies providing sufficient data to assess oncological outcomes (second local recurrence [LR] and overall survival [OS]) of rBCS for the management of IBCR after previous BCS and RT were included (PROSPERO registration CRD42021286123).
Forty-two observational studies met the criteria and were included in the analysis. The pooled second LR rate after rBCS was 15.7% (95% confidence interval [CI] 12.1-19.7), and 10.3% (95% CI 6.9-14.3) after salvage mastectomy. On meta-analysis of comparative studies (n = 17), the risk ratio (RR) for second LR following rBCS compared with mastectomy was 2.103 (95% CI 1.535-2.883; p < 0.001, I = 55.1%). Repeat RT had a protective effect (coefficient: - 0.317, 95% CI - 0.596 to - 0.038; p = 0.026, I = 40.4%) for second LR. Pooled 5-year OS was 86.8% (95% CI 83.4-90.0) and 79.8% (95% CI 74.7-84.5) for rBCS and salvage mastectomy, respectively. Meta-analysis of comparative studies (n = 20) showed a small OS benefit in favor of rBCS (RR 1.040, 95% CI 1.003-1.079; p = 0.032, I = 70.8%). Overall evidence certainty was very low.
This meta-analysis suggests rBCS could be considered as an option for the management of IBCR in patients previously treated with BCS and RT. Shared decision making, appropriate patient selection, and individualized approach are important for optimal outcomes.
对于先前接受过保乳手术(BCS)和放疗(RT)的同侧乳腺癌复发(IBCR)患者,标准的手术治疗方法是乳房切除术。最近的国际指南提供了相互矛盾的建议。本研究旨在对先前接受 BCS 和 RT 治疗后接受重复 BCS(rBCS)治疗的 IBCR 患者的肿瘤学结局进行系统的文献复习和荟萃分析。
检索 MEDLINE 和 EMBASE 数据库中与先前接受过 BCS 和 RT 治疗后接受 rBCS 治疗 IBCR 的患者的肿瘤学结局(第二次局部复发[LR]和总生存[OS])相关的英文文献,无时间限制。纳入所有提供足够数据评估 rBCS 治疗 IBCR 后肿瘤学结局(第二次 LR 和 OS)的相关研究(PROSPERO 注册号 CRD42021286123)。
42 项观察性研究符合标准并纳入分析。rBCS 后第二次 LR 率为 15.7%(95%置信区间[CI] 12.1-19.7),挽救性乳房切除术为 10.3%(95%CI 6.9-14.3)。对比较研究(n=17)的荟萃分析显示,rBCS 后第二次 LR 的风险比(RR)与乳房切除术相比为 2.103(95%CI 1.535-2.883;p<0.001,I=55.1%)。重复放疗具有保护作用(系数:-0.317,95%CI -0.596 至 -0.038;p=0.026,I=40.4%),可降低第二次 LR 的风险。rBCS 和挽救性乳房切除术的 5 年 OS 分别为 86.8%(95%CI 83.4-90.0)和 79.8%(95%CI 74.7-84.5)。对比较研究(n=20)的荟萃分析显示,rBCS 有轻微的 OS 获益(RR 1.040,95%CI 1.003-1.079;p=0.032,I=70.8%)。总体证据确定性非常低。
本荟萃分析表明,rBCS 可作为先前接受过 BCS 和 RT 治疗的 IBCR 患者的治疗选择之一。共同决策、适当的患者选择和个体化方法对于获得最佳结果至关重要。